NCT04900337View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Covid19

Interventions

DRUG

AMOR 18 Powder & Inhalation

AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual

DRUG

Placebo

Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual

Trial Locations (3)

Unknown

Shamir MC, Be’er Ya‘aqov

Ziv MC, Safed

Tel-Aviv Sourasky MC, Tel Aviv

All Listed Sponsors

lead

Amorphical Ltd.

INDUSTRY

NCT04900337 - Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients. | Biotech Hunter | Biotech Hunter